Your browser doesn't support javascript.
loading
ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance.
Stieg, David C; Wang, Yifang; Liu, Ling-Zhi; Jiang, Bing-Hua.
Affiliation
  • Stieg DC; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Wang Y; Department of Pathology, Anatomy & Cell Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Liu LZ; Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Jiang BH; Department of Pathology, Anatomy & Cell Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA.
Int J Mol Sci ; 23(12)2022 Jun 16.
Article in En | MEDLINE | ID: mdl-35743145
ABSTRACT
The diverse repertoires of cellular mechanisms that progress certain cancer types are being uncovered by recent research and leading to more effective treatment options. Ovarian cancer (OC) is among the most difficult cancers to treat. OC has limited treatment options, especially for patients diagnosed with late-stage OC. The dysregulation of miRNAs in OC plays a significant role in tumorigenesis through the alteration of a multitude of molecular processes. The development of OC can also be due to the utilization of endogenously derived reactive oxygen species (ROS) by activating signaling pathways such as PI3K/AKT and MAPK. Both miRNAs and ROS are involved in regulating OC angiogenesis through mediating multiple angiogenic factors such as hypoxia-induced factor (HIF-1) and vascular endothelial growth factor (VEGF). The NAPDH oxidase subunit NOX4 plays an important role in inducing endogenous ROS production in OC. This review will discuss several important miRNAs, NOX4, and ROS, which contribute to therapeutic resistance in OC, highlighting the effective therapeutic potential of OC through these mechanisms.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / MicroRNAs Limits: Female / Humans Language: En Year: 2022 Type: Article

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / MicroRNAs Limits: Female / Humans Language: En Year: 2022 Type: Article